GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
GO:190332216 | Esophagus | ESCC | positive regulation of protein modification by small protein conjugation or removal | 99/8552 | 138/18723 | 4.39e-10 | 1.16e-08 | 99 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:003464413 | Esophagus | ESCC | cellular response to UV | 70/8552 | 90/18723 | 4.59e-10 | 1.20e-08 | 70 |
GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
GO:190331316 | Esophagus | ESCC | positive regulation of mRNA metabolic process | 87/8552 | 118/18723 | 5.10e-10 | 1.32e-08 | 87 |
GO:0043620111 | Esophagus | ESCC | regulation of DNA-templated transcription in response to stress | 46/8552 | 53/18723 | 5.17e-10 | 1.33e-08 | 46 |
GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
GO:004682417 | Esophagus | ESCC | positive regulation of nucleocytoplasmic transport | 52/8552 | 62/18723 | 5.40e-10 | 1.38e-08 | 52 |
GO:005117014 | Esophagus | ESCC | import into nucleus | 111/8552 | 159/18723 | 5.69e-10 | 1.44e-08 | 111 |
GO:006101319 | Esophagus | ESCC | regulation of mRNA catabolic process | 115/8552 | 166/18723 | 5.90e-10 | 1.49e-08 | 115 |
GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:004348719 | Esophagus | ESCC | regulation of RNA stability | 117/8552 | 170/18723 | 7.91e-10 | 1.94e-08 | 117 |
GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |